Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biogen
Biotech
Biogen ends Apellis research programs, cuts roles after buyout
Biogen isn’t wasting any time integrating its multibillion-dollar purchase of Apellis.
Eric Sagonowsky
Jun 26, 2026 9:56am
Biogen inks $1B RayThera buyout to bag immunology assets
Jun 18, 2026 4:10am
Biogen is remaking its pipeline with an ‘entrepreneurial spirit’
Jun 16, 2026 8:50am
Biogen axes Denali-partnered Parkinson’s drug after phase 2 flop
May 22, 2026 6:12am
Biogen advances Alzheimer’s tau program despite midphase miss
May 14, 2026 8:35am
Biogen inks $850M deal with TJ for China rights antibody
Apr 20, 2026 10:26am
